First Foundation Advisors Gilead Sciences, Inc. Transaction History

First Foundation Advisors

$2.58 Billion
Q3 2024

A detailed history of First Foundation Advisors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, First Foundation Advisors holds 23,603 shares of GILD stock, worth $2.23 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

23,603

Previous 23,201 1.73%

Holding current value

$2.23 Million

Previous $1.59 Million 24.32%

% of portfolio

0.08%

Previous 0.06%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$66.59 - $83.99 $26,769 - $33,763	402 Added 1.73%	23,603 $1.98 Million
Q2 2024 Aug 06, 2024	SELL	$63.15 - $72.88 $16,103 - $18,584	-255 Reduced 1.09%	23,201 $1.59 Million
Q1 2024 May 09, 2024	SELL	$71.58 - $87.29 $765,190 - $933,130	-10,690 Reduced 31.31%	23,456 $1.72 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $1.11 Million - $1.25 Million	-15,103 Reduced 30.67%	34,146 $2.77 Million
Q3 2023 Nov 15, 2023	SELL	$73.94 - $80.67 $57,525 - $62,761	-778 Reduced 1.56%	49,249 $3.69 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $71,221 - $81,237	937 Added 1.91%	50,027 $3.86 Million
Q1 2023 May 12, 2023	SELL	$77.31 - $88.08 $858,682 - $978,304	-11,107 Reduced 18.45%	49,090 $4.07 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $110,057 - $158,004	-1,766 Reduced 2.85%	60,197 $5.17 Million
Q3 2022 Nov 10, 2022	SELL	$59.54 - $68.01 $17,564 - $20,062	-295 Reduced 0.47%	61,963 $3.82 Million
Q2 2022 Aug 12, 2022	BUY	$57.72 - $65.01 $108,455 - $122,153	1,879 Added 3.11%	62,258 $3.85 Million
Q1 2022 May 05, 2022	SELL	$57.92 - $72.58 $242,047 - $303,311	-4,179 Reduced 6.47%	60,379 $3.59 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $238,109 - $270,258	3,670 Added 6.03%	64,558 $4.69 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $36,011 - $38,851	532 Added 0.88%	60,888 $4.25 Million
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $5,521 - $6,033	87 Added 0.14%	60,356 $4.16 Million
Q1 2021 May 18, 2021	SELL	$60.0 - $68.46 $31,980 - $36,489	-533 Reduced 0.88%	60,269 $3.9 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $4,305 - $4,905	76 Added 0.13%	60,802 $3.54 Million
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $111,904 - $140,700	-1,802 Reduced 2.88%	60,726 $3.84 Million
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $91,293 - $106,008	-1,262 Reduced 1.98%	62,528 $4.81 Million
Q1 2020 May 11, 2020	BUY	$62.63 - $80.22 $138,913 - $177,927	2,218 Added 3.6%	63,790 $4.77 Million
Q4 2019 Feb 11, 2020	BUY	$61.62 - $67.78 $30,563 - $33,618	496 Added 0.81%	61,572 $4 Million
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $38,631 - $42,642	-618 Reduced 1.0%	61,076 $3.87 Million
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $85,133 - $95,466	-1,376 Reduced 2.18%	61,694 $4.17 Million
Q1 2019 May 13, 2019	SELL	$62.53 - $70.05 $5,940 - $6,654	-95 Reduced 0.15%	63,070 $4.1 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $59,571 - $77,736	-984 Reduced 1.53%	63,165 $3.95 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $129,373 - $143,239	-1,815 Reduced 2.75%	64,149 $4.95 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $66,307 - $77,344	1,022 Added 1.57%	65,964 $4.67 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $150,341 - $183,283	-2,064 Reduced 3.08%	64,942 $4.9 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $1.95 Million - $2.28 Million	-27,342 Reduced 28.98%	67,006 $4.8 Million
Q3 2017 Nov 14, 2017	SELL	$72.11 - $85.47 $1.01 Million - $1.19 Million	-13,961 Reduced 12.89%	94,348 $7.64 Million
Q2 2017 Aug 14, 2017	BUY	N/A	108,309	108,309 $7.67 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Foundation Advisors, based on Form 13F filings with the SEC.

News

Stay updated on First Foundation Advisors with notifications on news.

Account

First Foundation Advisors Gilead Sciences, Inc. Transaction History